课题基金 / 基金详情

Postdoctoral Training in Drug Abuse Research: Behavior & Neurobiology

Postdoctoral Training in Drug Abuse Research: Behavior & Neurobiology
药物滥用研究博士后培训:行为
批准号:
10403619
负责人:
CHARLES P FRANCE
金额:
$46.33万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-07-01 至 2026-06-30

项目摘要

项目成果

CHARLES P FRANCE的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 此应用程序响应PA-20-142,是博士后的第二个竞争延续 德克萨斯大学题为“药物滥用研究培训:行为和神经生物学”的培训方案 圣安东尼奥健康科学中心(UTHSCSA)。该计划已成为一个组成部分, 最近推出了成瘾研究,治疗和培训卓越中心,伞式组织, 大量的各种活动有关的物质使用障碍(SUD)在校园内,并延伸到圣 安东尼奥社区在本支助期间,所有6个培训职位都由选定的研究员填补 从一群高素质的申请者中脱颖而出自2016年以来,共有14名学员已经或正在 在该方案的支助下,有11名妇女(78%); 4名受训人员(28%)是代表性不足的少数民族。 在完成培训的10名研究员中,8人担任学术职务。在目前的支助期间, 学员发表了40篇手稿(28篇为第一作者),提交了11份赠款申请, 在科学会议上发言。越来越多的受训人员参加社区推广活动, 倡导SUD研究,教育和治疗。该计划赞助了许多职业发展 除了该方案的受训人员外,学生和研究员也参加了许多活动。井- 18名普通教师和3名初级教师导师的资助研究项目涵盖细胞信号传导到神经化学, 临床前行为药理学和人体临床试验。该计划享有杰出的财政和 来自UTHSCSA的其他支持(例如,主任10%的工资),包括博士后事务办公室, 提供了许多关于职业发展、赠款写作和教学等方面的课程。项目领导 包括一名主任、副主任、协调员和内部咨询委员会。一个外部咨询 作为在圣安东尼奥举行的年度咨询委员会会议的一部分,委员会评估该计划;详细信息 方案的运作以及研究员的培训经验都得到了改善, 咨询委员会的建议。UTHSCSA的培训环境非常出色, 包括优秀的研讨会,盛大的回合,期刊俱乐部(包括成瘾期刊俱乐部主办的这 程序),严格性和再现性的正式培训,负责任的研究行为的正式培训,以及 一年一度的国际SUD会议,题为行为,生物学和化学:转化研究, 成瘾这一竞争性续设要求为这一高度优先事项中的6个职位再提供5年支助。 一个成功的,充满活力的计划,这是有助于NIDA的使命招募和培训下一代 SUD研究人员。
英文摘要
ABSTRACT This application responds to PA-20-142 and is the second competing continuation of a postdoctoral training program entitled “Training in drug abuse research: behavior and neurobiology” at the University of Texas Health Science Center at San Antonio (UTHSCSA). This Program has become an integral component of the recently launched Addiction Research, Treatment & Training Center of Excellence, the umbrella organization for a large variety of activities related to substance use disorder (SUD) on campus and extending into the San Antonio community. During the current period of support, all 6 training positions were filled with fellows selected from a pool of highly qualified applications. Since 2016, a total of 14 trainees have been or are currently supported by the Program, including 11 women (78%); 4 of the trainees (28%) are underrepresented minorities. Among 10 fellows that completed training, 8 are in academic positions. During the current period of support, trainees published 40 manuscripts (28 as first author), submitted 11 grant applications, and made 111 presentations at scientific meetings. Increasingly trainees are participating in community outreach activities, advocating for SUD research, education, and treatment. This Program sponsors numerous career development activities, many of which are attended by students and fellows, in addition to trainees in this Program. The well- funded research programs of the 18 Regular and 3 Junior faculty mentors span cell signaling to neurochemistry, preclinical behavioral pharmacology, and human clinical trials. The Program enjoys outstanding financial and other support from UTHSCSA (e.g., 10% salary for the Director), including an Office of Postdoctoral Affairs that offers many programs on career development, grant writing, and teaching, among others. Program Leadership includes a Director, Associate Director, Coordinator, and an Internal Advisory Committee. An External Advisory Committee evaluates the Program as part of an annual Advisory Committee Meeting in San Antonio; the details and operation of the Program as well as the training experience of fellows have improved as a result of recommendations by the Advisory Committees. The training environment at UTHSCSA is outstanding and includes excellent seminars, grand rounds, journal clubs (including the Addiction Journal Club hosted by this Program), formal training in rigor and reproducibility, formal training in the responsible conduct of research, and an annual international SUD meeting entitled Behavior, Biology & Chemistry: Translational Research in Addiction. This competing continuation requests 5 additional years of support for 6 positions in this highly successful, vibrant Program that is contributing to the NIDA mission of recruiting and training the next generation of SUD researchers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Methocinnamox (MCAM): A novel opioid receptor antagonist
A novel opioid receptor antagonist for treating abuse and overdose
A novel opioid receptor antagonist for treating abuse and overdose
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
海外基金